Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01779791 · ClinicalTrials.gov registry record · Phase 2
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT01779791 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 110 participants.
The verdict
NCT01779791, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).
Interventions
- DRUG PCI-32765 (Ibrutinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2013-04-17 |
| Est. Completion | 2016-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01779791
The ClinicalTrials.gov registry entry for NCT01779791 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PCI-32765 (Ibrutinib) is the first listed.
NCT01779791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01779791 about?
NCT01779791 is a clinical study titled "A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma". The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).
What is the current status of trial NCT01779791?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2013-04-17. Estimated completion is 2016-05-18.
What interventions are being tested in trial NCT01779791?
The interventions under investigation include: PCI-32765 (Ibrutinib) (DRUG).
Who is sponsoring clinical trial NCT01779791?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.